Screener Summaries Updates Institutions Sign In More Updates › Other Events › CANF Other Events · Jul 1, 2026
On July 1, 2026, Can-Fite BioPharma Ltd. announced that its Phase 2a study of Namodenoson for pancreatic cancer… CANF Can-Fite BioPharma Ltd.
On July 1, 2026, Can-Fite BioPharma Ltd. announced that its Phase 2a study of Namodenoson for pancreatic cancer achieved its primary safety endpoint and demonstrated durable survival outcomes in patients with advanced disease. The company operates in the biotechnology industry and develops therapeutic candidates for various diseases.
More from Can-Fite BioPharma Ltd. EAPO allows patent for Piclidenoson in Lowe syndrome, strengthening IP foundation Nov 2, 2026 Presents final positive Phase IIa data for namodenoson in pancreatic cancer, achieving primary safety endpoint Oct 26, 2026 Can-Fite BioPharma Ltd. reported H1 2026 financial results showing a net loss of $4.6 million, compared to $4.87… Sep 8, 2026 On September 2, 2026, Can-Fite Biopharma Ltd. entered into an inducement offer letter with a warrant holder to… Sep 3, 2026 Can-Fite BioPharma Ltd. announced the exercise of outstanding warrants for approximately $4.0 million in gross… Sep 2, 2026 All content on this site is for informational purposes only and does not constitute financial, investment, legal, or tax advice. Past performance is not indicative of future results. Always consult a qualified financial advisor before making investment decisions.
Financial data is obtained from public filings and third-party providers and is provided “as-is” without any guarantee of accuracy, completeness, or timeliness.
© 2026 go-intrinsic.com. All rights reserved.
